DR. SCOTT KOENIG, M.D.
Osteopathic Medicine at Medical Center Dr, Rockville, MD
License number
Maryland D0031731
Category
Osteopathic Medicine
Type
Allergy & Immunology
License number
Maryland D0031731
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
9640 Medical Center Dr, Rockville, MD 20850
Phone
(301) 354-0680
(301) 251-5321 (Fax)
(301) 251-5321 (Fax)
Personal information
See more information about SCOTT KOENIG at radaris.comName
Address
Phone
477 Streaker Rd, Sykesville, MD 21784
9501 Traverse Way, Ft Washington, MD 20744
Professional information
Derivatives Of Choline Binding Proteins For Vaccines
US Patent:
6503511, Jan 7, 2003
Filed:
Apr 6, 1999
Appl. No.:
09/286981
Inventors:
Theresa M. Wizemann - Potomac MD
Scott Koenig - Rockville MD
Leslie S. Johnson - Germantown MD
Scott Koenig - Rockville MD
Leslie S. Johnson - Germantown MD
Assignee:
MedImmune, Inc. - Gaithersburg MD
International Classification:
A61K 3902
US Classification:
4241901, 4241841, 4242341, 4242371, 4242441, 530300, 530350, 514 2, 514 8
Abstract:
The present invention provides bacterial immunogenic agents for administration to humans and non-human animals to stimulate an immune response. It particularly relates to the vaccination of mammalian species with pneumococcal derived polypeptides that include an alpha helix but exclude a choline binding region as a mechanism for stimulating production of antibodies that protect the vaccine recipient against infection by pathogenic bacterial species. In another aspect the invention provides antibodies against such proteins and protein complexes that may be used as diagnositics and/or as protective/treatment agents for pathogenic bacterial species.
Methods Of Enhancing Activity Of Vaccines And Vaccine Compositions
US Patent:
6565849, May 20, 2003
Filed:
Mar 2, 2001
Appl. No.:
09/797760
Inventors:
Scott Koenig - Rockville MD
Assignee:
MedImmune, Inc. - Gaithersburg MD
International Classification:
A61K 3942
US Classification:
4241471, 4241481, 4241491, 4241551, 4242041, 4242061, 4242081, 4242111, 4242261, 4242271, 4242341, 4242361, 4242771
Abstract:
Disclosed are methods for vaccine priming, using co-treatment, at a temporally similar or at a previous time, with a priming antibody capable of priming, or enhancing, or potentiating the effects of a vaccine, or vaccine composition. Also disclosed are methods of using this process to prevent or treat disease.
Fcgammariib Specific Antibodies And Methods Of Use Thereof
US Patent:
2009007, Mar 19, 2009
Filed:
Aug 5, 2008
Appl. No.:
12/186065
Inventors:
Scott Koenig - Rockville MD, US
Maria Concetta Veri - Denwood MD, US
Nadine Tuaillon - Gettysburg PA, US
Ezio Bonvini - Rockville MD, US
Maria Concetta Veri - Denwood MD, US
Nadine Tuaillon - Gettysburg PA, US
Ezio Bonvini - Rockville MD, US
Assignee:
MACROGENICS, INC. - Rockville MD
International Classification:
A61K 39/395, G01N 33/53, A61P 37/02
US Classification:
4241361, 435 72, 435 721, 435 724
Abstract:
The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, more particularly the extracellular domain of FcγRIIB with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA, and block the Fc binding site of FcγRIIB. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in amounts effective to prevent, treat, manage, or ameliorate a cancer, such as a B-cell malignancy, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention further provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention with a vaccine composition. The invention further provides methods of treating cancer and/or regulating immune complex-mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.
Polypeptide Comprising The Amino Acid Of An N-Terminal Choline Binding Protein A Truncate, Vaccine Derived Therefrom And Uses Thereof
US Patent:
2005020, Sep 22, 2005
Filed:
Jan 10, 2005
Appl. No.:
11/032644
Inventors:
Elaine Tuomanen - Germantown TN, US
Theresa Wizemann - North Potomac MD, US
H. Masure - Leawood KS, US
Leslie Johnson - Germantown MD, US
Scott Koenig - Rockville MD, US
Theresa Wizemann - North Potomac MD, US
H. Masure - Leawood KS, US
Leslie Johnson - Germantown MD, US
Scott Koenig - Rockville MD, US
Assignee:
St. Jude Children's Research Hospital - Memphis TN
Medimmune, Inc. - Gaithersburg MD
Medimmune, Inc. - Gaithersburg MD
International Classification:
C12Q001/68, C07H021/04, A61K039/02, C12N015/74
US Classification:
424190100, 435006000, 435069100, 435252300, 435320100, 530350000, 536023700
Abstract:
This invention provides an isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate in which the amino acid sequence is set forth in any of SEQ ID NOS: 1, 3-7, or 9-11, including fragments, mutants, variants, analogs, or derivatives, thereof. Also, this invention provides a isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate, wherein the amino acid is set forth in SEQ ID NO: 24, wherein the polypeptide retains its native tertiary structure and methods of preparation. This invention provides an isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate, wherein the polypeptide has lectin activity and does not bind to choline. This invention provides an isolated immunogenic polypeptide comprising an amino acid sequence of a N— terminal choline binding protein A truncate. This invention provides an isolated nucleic acid encoding a polypeptide comprising an amino acid sequence of a N— terminal choline binding protein A truncate. Lastly, this invention provides pharmaceutical compositions, vaccines, and diagnostic and therapeutic methods of use.
Methods Of Administering/Dosing Anti-Rsv Antibodies For Prophylaxis And Treatment
US Patent:
7229619, Jun 12, 2007
Filed:
Nov 28, 2000
Appl. No.:
09/724531
Inventors:
James F. Young - Potomac MD, US
Scott Koenig - Rockville MD, US
Leslie S. Johnson - Germantown MD, US
William D. Huse - Del Mar CA, US
Jeffrey D. Watkins - Encinitis CA, US
Herren Wu - Germantown MD, US
Scott Koenig - Rockville MD, US
Leslie S. Johnson - Germantown MD, US
William D. Huse - Del Mar CA, US
Jeffrey D. Watkins - Encinitis CA, US
Herren Wu - Germantown MD, US
Assignee:
MedImmune, Inc. - Gaithersburg MD
International Classification:
A61K 39/42
US Classification:
4241591, 4241301, 4241341, 4241411, 4241471, 4242111
Abstract:
The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis a RSV infection.
Methods Of Administering/Dosing Anti-Rsv Antibodies For Prophylaxis And Treatment
US Patent:
7635568, Dec 22, 2009
Filed:
Jul 26, 2004
Appl. No.:
10/900230
Inventors:
James F. Young - Potomac MD, US
Scott Koenig - Rockville MD, US
Leslie S. Johnson - Germantown MD, US
William D. Huse - Del Mar CA, US
Jeffrey D. Watkins - Encinitis CA, US
Herren Wu - Boyds MD, US
Scott Koenig - Rockville MD, US
Leslie S. Johnson - Germantown MD, US
William D. Huse - Del Mar CA, US
Jeffrey D. Watkins - Encinitis CA, US
Herren Wu - Boyds MD, US
Assignee:
MedImmune, LLC - Gaithersburg MD
International Classification:
G01N 33/53, A61K 39/12, A61K 39/42
US Classification:
435 71, 4241411, 4241471, 4242111
Abstract:
The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis a RSV infection.
Methods Of Administering/Dosing Anti-Rsv Antibodies For Prophylaxis And Treatment
US Patent:
7179900, Feb 20, 2007
Filed:
Mar 31, 2003
Appl. No.:
10/403180
Inventors:
James F. Young - Potomac MD, US
Scott Koenig - Rockville MD, US
Leslie S. Johnson - Germantown MD, US
William D. Huse - Del Mar CA, US
Jeffrey D. Watkins - Encinitis CA, US
Herren Wu - Boyds MD, US
Scott Koenig - Rockville MD, US
Leslie S. Johnson - Germantown MD, US
William D. Huse - Del Mar CA, US
Jeffrey D. Watkins - Encinitis CA, US
Herren Wu - Boyds MD, US
Assignee:
MedImmune, Inc. - Gaithersburg MD
International Classification:
A61K 39/42, A61K 39/155
US Classification:
536 2353, 4241591, 4242111
Abstract:
The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis of a RSV infection.
Fcgammariib Specific Antibodies And Methods Of Use Thereof
US Patent:
2009009, Apr 9, 2009
Filed:
Jul 3, 2008
Appl. No.:
12/167765
Inventors:
Scott Koenig - Rockville MD, US
Maria Concetta Veri - Denwood MD, US
Nadine Tuaillon - Gettysburg PA, US
Maria Concetta Veri - Denwood MD, US
Nadine Tuaillon - Gettysburg PA, US
Assignee:
MACROGENICS, INC. - Rockville MD
International Classification:
A61K 39/395, C07K 16/28, A61P 35/00
US Classification:
4241361, 53038822, 4241431, 4241331, 5303873
Abstract:
The present invention relates to antibodies or fragments thereof that specifically bind the extracellular domain of FcγRIIB, particularly human FcγRIIB, and block the Fc binding site of human FcγRIIB. The invention provides methods of treating cancer and/or regulating immune complex-mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.
Epitope-Based Vaccine For Respiratory Syncytial Virus F-Protein
US Patent:
2002001, Feb 14, 2002
Filed:
May 25, 2001
Appl. No.:
09/865499
Inventors:
Scott Koenig - Rockville MD, US
Mark Hanson - Clarksville MD, US
JoAnn Suzich - Washington Grove MD, US
Nancy Ulbrandt - Gaithersburg MD, US
Mark Hanson - Clarksville MD, US
JoAnn Suzich - Washington Grove MD, US
Nancy Ulbrandt - Gaithersburg MD, US
International Classification:
A61K039/12, A61K039/42
US Classification:
424/186100, 424/147100
Abstract:
The present invention relates to a vaccine that comprises selected epitopes within the F protein structure that have been proven to specifically interact with known potent neutralizing antibodies while simultaneously being presented as part of a synthetic structure that offers these epitopes apart from the other non-neutralizing antigenic determinants of the virus but held in a native conformational form and thereby capable of eliciting neutralizing antibodies.
Fcgammariib Specific Antibodies And Methods Of Use Thereof
US Patent:
2009001, Jan 15, 2009
Filed:
Jul 3, 2008
Appl. No.:
12/167784
Inventors:
Scott Koenig - Rockville MD, US
Maria Concetta Veri - Denwood MD, US
Maria Concetta Veri - Denwood MD, US
Assignee:
MACROGENICS, INC. - Rockville MD
International Classification:
A61K 39/395, C07K 16/28, C07K 16/46
US Classification:
4241331, 5303891, 5303873, 5303917, 4241721
Abstract:
The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.